Literature DB >> 30262242

Competing tumor cell migration mechanisms caused by interstitial fluid flow.

Jahn O Waldeland1, Steinar Evje2.   

Abstract

In the seminal work by Swartz and collaborators (Shields et al., 2007) it was discovered that autologously secreted or activated (ECM-bound) chemokine forms local pericellular diffusion gradients skewed by fluid convection, and the cells subsequently chemotact up the flow-directed gradient. However, in (Polacheck et al., 2011) Kamm and collaborators found that there is a competing downstream and upstream migration transport mechanism. Their study showed that both mechanisms are present at the same time and the relative strength of these two stimuli governs the directional bias in migration for a cell population and is a function of cell density, interstitial flow rate, and CCR7 receptor availability. The main objective of this work is to give a possible explanation of these two different concurrent cell migration mechanisms by means of a theoretical model. Relying on multiphase modelling, separate momentum balance equations are formulated, respectively, for the cell phase and the interstitial fluid (IF) phase. In order to represent proteolytic activity and autologous chemotaxis a non-moving ECM component is included, as well as proteases secreted by the cancer cells and chemokine that can be released from ECM. The cell and IF momentum balance equations include cell-ECM and fluid-ECM resistance force terms (i.e., classical Darcy's equation terms), but also a cell-fluid interaction term that can account for a more indirect effect that fluid-generated stress may have on cancer cells. We illustrate how the cancer cells can work through this term and effectively avoid being pushed in the flow direction, and even create upstream migration by controlling its magnitude and sign. We think of this as the mathematical interpretation of the experimental observation by Kamm and collaborators that the fluid generated matrix adhesion tension on the upstream side of cells activates integrin adhesion complexes, resulting in activation of focal adhesion (FA) proteins. The model predicts that generally the strength of the upstream migration mechanism is sensitive to the cell volume fraction: a lower density of cells is subject to a weaker upstream migration effect; a higher density of cancer cells can more effectively generate upstream migration. This behavior is a result of the nonlinear coupling between cell-ECM, fluid-ECM, and cell-fluid interaction terms that naturally are involved in the mathematical expression for the net cell velocity.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell-migration; Chemotaxis; Interstitial fluid; Interstitial fluid pressure; Lymphatic flow; Mechanotransductive; Multiphase flow; Rheotaxis; Vascular flow

Mesh:

Year:  2018        PMID: 30262242     DOI: 10.1016/j.jbiomech.2018.09.011

Source DB:  PubMed          Journal:  J Biomech        ISSN: 0021-9290            Impact factor:   2.712


  4 in total

1.  Microfluidics for the study of mechanotransduction.

Authors:  Christian M Griffith; Stephanie A Huang; Crescentia Cho; Tanmay M Khare; Matthew Rich; Gi-Hun Lee; Frances S Ligler; Brian O Diekman; William J Polacheck
Journal:  J Phys D Appl Phys       Date:  2020-04-02       Impact factor: 3.207

2.  How Tumor Cells Can Make Use of Interstitial Fluid Flow in a Strategy for Metastasis.

Authors:  Steinar Evje; Jahn Otto Waldeland
Journal:  Cell Mol Bioeng       Date:  2019-03-27       Impact factor: 2.321

3.  Collective tumor cell migration in the presence of fibroblasts.

Authors:  Jahn O Waldeland; William J Polacheck; Steinar Evje
Journal:  J Biomech       Date:  2019-12-19       Impact factor: 2.789

4.  Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins.

Authors:  Bart Kramer; Luuk de Haan; Marjolein Vermeer; Thomas Olivier; Thomas Hankemeier; Paul Vulto; Jos Joore; Henriëtte L Lanz
Journal:  Int J Mol Sci       Date:  2019-09-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.